SM: General Electric unit GE Healthcare said today it has agreed to buy cancer diagnostic company Clarient. Clarient shareholders will receive $5 per common share and $20 per preferred share, each payable in cash. The transaction values Clarient at [$]580 million. Clarient's role in the molecular diagnostics sector, combined with GE Healthcare's strengths in diagnostic imaging, are expected to accelerate the development of new integrated tools for the diagnosis and characterization of cancer, according to the companies. GE Healthcare estimates that the global demand for cancer-profiling products and services is predicted to grow from [$]15 billion in 2009, to [$]47 billion by 2015. The companies said the transaction is expected to close late this year or early next year. For MarketNewsVideo.com, I'm Sayoko Murase.
标题
GE Healthcare Buys Clarient (MNV)
视频介绍
Market News Video - October 22, 2010
GE Healthcare has agreed to buy cancer diagnostic company Clarient.
